Cargando…
Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine
Introduction: Inflammatory bowel diseases (IBDs) are lifelong conditions causing relapsing inflammation of the intestine. In the absence of a cure, clinical management of IBDs is extremely challenging since they present with a wide range of phenotypes and disease behaviors. Hence, there is an urgent...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903817/ https://www.ncbi.nlm.nih.gov/pubmed/34142929 http://dx.doi.org/10.1080/1744666X.2021.1945442 |
_version_ | 1784664851553976320 |
---|---|
author | Giachero, Federica Jenke, Andreas Zilbauer, Matthias |
author_facet | Giachero, Federica Jenke, Andreas Zilbauer, Matthias |
author_sort | Giachero, Federica |
collection | PubMed |
description | Introduction: Inflammatory bowel diseases (IBDs) are lifelong conditions causing relapsing inflammation of the intestine. In the absence of a cure, clinical management of IBDs is extremely challenging since they present with a wide range of phenotypes and disease behaviors. Hence, there is an urgent need for markers that could guide physicians in making the right choice of the rapidly growing treatment options toward a personalized care that could improve the overall outcome. Areas covered: In this review, the authors summarize existing biomarkers in IBD, discuss the challenges with the development of prognostic biomarkers and propose alternative options such as focusing on the prediction of the response to individual treatments, i.e. predictive biomarkers. The problems related to developing disease prognostic and predictive biomarkers in the field of IBDs are discussed including the difficulties in dealing with phenotypic heterogeneity particularly when performing studies in a real-life setting. The authors reviewed literature from PubMed. Expert opinion: Systems biology provides potential solutions to this problem by offering an unbiased, holistic approach to adjusting for variation in larger datasets thereby increasing the chances of identifying true associations between molecular profiles and clinical phenotypes. |
format | Online Article Text |
id | pubmed-8903817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-89038172022-03-09 Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine Giachero, Federica Jenke, Andreas Zilbauer, Matthias Expert Rev Clin Immunol Review Introduction: Inflammatory bowel diseases (IBDs) are lifelong conditions causing relapsing inflammation of the intestine. In the absence of a cure, clinical management of IBDs is extremely challenging since they present with a wide range of phenotypes and disease behaviors. Hence, there is an urgent need for markers that could guide physicians in making the right choice of the rapidly growing treatment options toward a personalized care that could improve the overall outcome. Areas covered: In this review, the authors summarize existing biomarkers in IBD, discuss the challenges with the development of prognostic biomarkers and propose alternative options such as focusing on the prediction of the response to individual treatments, i.e. predictive biomarkers. The problems related to developing disease prognostic and predictive biomarkers in the field of IBDs are discussed including the difficulties in dealing with phenotypic heterogeneity particularly when performing studies in a real-life setting. The authors reviewed literature from PubMed. Expert opinion: Systems biology provides potential solutions to this problem by offering an unbiased, holistic approach to adjusting for variation in larger datasets thereby increasing the chances of identifying true associations between molecular profiles and clinical phenotypes. Taylor & Francis 2021-06-28 /pmc/articles/PMC8903817/ /pubmed/34142929 http://dx.doi.org/10.1080/1744666X.2021.1945442 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Giachero, Federica Jenke, Andreas Zilbauer, Matthias Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine |
title | Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine |
title_full | Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine |
title_fullStr | Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine |
title_full_unstemmed | Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine |
title_short | Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine |
title_sort | improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903817/ https://www.ncbi.nlm.nih.gov/pubmed/34142929 http://dx.doi.org/10.1080/1744666X.2021.1945442 |
work_keys_str_mv | AT giacherofederica improvingpredictionofdiseaseoutcomeforinflammatoryboweldiseaseprogressthroughsystemsmedicine AT jenkeandreas improvingpredictionofdiseaseoutcomeforinflammatoryboweldiseaseprogressthroughsystemsmedicine AT zilbauermatthias improvingpredictionofdiseaseoutcomeforinflammatoryboweldiseaseprogressthroughsystemsmedicine |